Results 181 to 190 of about 38,488 (237)

Immune Response to MVA-BN Vaccination for Mpox: Current Evidence and Future Directions. [PDF]

Vaccines (Basel)
Byrne J, Katoto PDMC, Kirenga B, Sabiiti W, Obuku A, Gautier V, Mallon PWG, Feeney ER.   +7 more
europepmc   +1 more source

Correction for Oom et al., "The two-dose MVA-BN mpox vaccine induces a nondurable and low avidity MPXV-specific antibody response". [PDF]

J Virol
Oom AL, Wilson KK, Yonatan M, Rettig S, Youn HA, Tuen M, Shah Y, DuMont AL, Belli HM, Zucker JR, Rosen JB, Herati RS, Samanovic MI, Duerr R, Kottkamp AC, Mulligan MJ, NYC OSMI Study Group.   +16 more
europepmc   +1 more source

Antibody Responses are Sustained 2 Years Post-Mpox Infection but not Following Modified Vaccinia Ankara-Bavarian Nordic Vaccination. [PDF]

Open Forum Infect Dis
Byrne J, Garcia-Leon A, Murphy A, Saini G, Banik I, Landay A, Luong Nguyen LB, Savinelli S, O'Broin C, Horgan M, Kelly C, Mejia-Chew C, Sadlier C, de Barra E, O'Halloran JA, Gautier V, Mallon PWG, Feeney ER.   +17 more
europepmc   +1 more source

Safety and Efficacy of Repurposed Smallpox Vaccines Against Mpox: A Critical Review of ACAM2000, JYNNEOS, and LC16. [PDF]

J Epidemiol Glob Health
Wahid M, Mandal RK, Sikander M, Khan MR, Haque S, Nagda N, Ahmad F, Rodriguez-Morales AJ.   +7 more
europepmc   +1 more source

Potential of MRNA vaccines for mpox prevention: current evidence and future directions. [PDF]

Ann Med Surg (Lond)
Abdul-Rahman T, Faith OE, Ajetunmobi OA, Thaalibi HI, Ikele CG, Gautam G, Omotayo FO, Roy P, Adebayo AA, Mojeed MA, Kareem TT, Ali HI, Atieno RG, Ademeta EO, Garg N, Ashinze P, Scott GY.   +16 more
europepmc   +1 more source